uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
15.74
-0.05 (-0.32%)
Jan 31, 2025, 4:00 PM EST - Market closed
uniQure Revenue
uniQure had revenue of $2.29M in the quarter ending September 30, 2024, with 62.54% growth. This brings the company's revenue in the last twelve months to $28.59M, down -74.45% year-over-year. In the year 2023, uniQure had annual revenue of $15.84M, down -85.12%.
Revenue (ttm)
$28.59M
Revenue Growth
-74.45%
P/S Ratio
26.64
Revenue / Employee
$59,556
Employees
480
Market Cap
767.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 63.17B |
| AbbVie | 56.33B |
| Novartis AG | 51.72B |
| AstraZeneca | 51.21B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
QURE News
- 2 days ago - uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewsWire
- 24 days ago - uniQure Announces Pricing of its Public Offering - GlobeNewsWire
- 24 days ago - uniQure Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease - GlobeNewsWire
- 2 months ago - uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy - GlobeNewsWire
- 3 months ago - uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 3 months ago - uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - GlobeNewsWire
- 4 months ago - uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire